pulmonary arterial hypertension

BPD: Complication of prematurity
BPD: Complication of prematurityDespite improvements in obstetric and neonatal care leading to increased survival of premature infants, little progress has been made in the prevention of bronchopulmonary dysplasia. Pediatricians need to be aware of changing definitions, risk factors, prevention, and long-term health outcomes of this disease in their premature patients.
FDA approves PAH treatmentSelexipag is a first-in-class oral treatment option to reduce progression and hospitalization for pulmonary arterial hypertension.
FDA approves drug for rare lung diseaseThe FDA recently granted orphan drug approval to Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.
Gilead sues to stop Actavis' generic bid for LetairisActavis plc on Friday said it filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) seeking approval to market Ambrisentan Tablets, a generic version of Gilead Sciences, Inc.'s Letairis®, a treatment for pulmonary arterial hypertension.
FDA drug approvals-April 2015FDA actions in brief, priority review, breakthrough therapy designation, fast-track designations, orphan drug designations, first-time generic approvals
First drug of new class available for PAHRiociguat (Adempas, Bayer Healthcare Pharmaceuticals Inc.) was approved by FDA on October 8, 2013 for two patient groups. It is intended for patients with pulmonary arterial hypertension (PAH) World Health Organization (WHO) group 1 to improve exercise capacity, improve WHO functional class, and delay clinical worsening. It is also approved for patients with pulmonary hypertension (PH) WHO Group IV who have inoperable or persistent/recurrent postoperative chronic thromboembolic pulmonary hypertension (CTEPH), with the intent of improving exercise capacity and WHO functional class.
Opsumit approved to treat pulmonary arterial hypertensionThe FDA has approved macitentan (Opsumit) to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating disease that can lead to death or lung transplantation.
Opsumit approved to treat pulmonary arterial hypertensionFDA approved macitentan (Opsumit, Actelion Pharmaceuticals) to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or lung transplantation.
Opsumit approved to treat pulmonary arterial hypertensionFDA approved macitentan (Opsumit, Actelion Pharmaceuticals) to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or lung transplantation.
FDA approves first drug to treat 2 forms of pulmonary hypertensionFDA approved riociguat (Adempas, Bayer HealthCare Pharmaceuticals) tablets for the treatment of adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH and adults with pulmonary arterial hypertension (PAH).